CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.17) by 19.66 percent. This is a 60.83 percent increase over losses of $(2.40) per share
CRISPR lost less money than people expected, and made more sales than predicted. When a company loses less money than expected, it shows they're getting better at managing costs while their business grows.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.